
BTK inhibitors play a crucial role in mantle cell lymphoma treatment, with evolving options and considerations for frontline and relapsed cases.


coremsg

Drs Peter Martin and Anita Kumar discuss covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors in the frontline setting, BTK mutations, and the complicated mechanisms of resistance.

Episode 6: Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma

bruton-tyrosine-kinase-inhibitors-in-mantle-cell-lymphoma-discussion


Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma Discussion
